Jadwal Sholat

Memuat jadwal sholatโ€ฆ

Kedokteran & Kesehatan editorial

Open AccessOA2023

VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial

In a phase 2 randomized trial, high-dose VE303 (8.0ร—10^9 CFUs) reduced CDI recurrence at 8 weeks to 13.8% vs 45.5% with placebo (P=0.006). The defined bacterial consortium of 8 commensal Clostridia strains was safe and warrants phase 3 investigation.
T. Louie; Y. Golan; S. Khanna; D. Bobilev; N. Erpelding; C. Fratazzi; Meg Carini; Rajita Menon; Mary M. Ruisi; J. Norman; J. Faith; B. Olle; Min-Ran Li; J. Silber; D. Pardiยท Journal of the American Medical Association (JAMA)ยท 2023ยท DOI 10.1001/jama.2023.4314

The core problem

Clostridioides difficile infection (CDI) is a major cause of healthcare-associated diarrhea, and recurrence after standard antibiotic treatment is common. The role of rationally defined nonpathogenic, nontoxigenic commensal Clostridia in preventing CDI recurrence is unknown. VE303 is a defined bacterial consortium of 8 strains of commensal Clostridia developed to restore colonization resistance. This phase 2 trial aimed to determine the efficacy of VE303 in adults at high risk for CDI recurrence and to identify the recommended dose for a phase 3 trial.

Innovation

This was a phase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from February 2019 to September 2021 at 27 sites in the US and Canada. Participants were aged 18 years or older with laboratory-confirmed CDI and either 1 or more prior CDI episodes in the last 6 months or primary CDI at high risk for recurrence (defined as age โ‰ฅ75 years or โ‰ฅ65 years with โ‰ฅ1 risk factor: creatinine clearance <60 mL/min/1.73 mยฒ, proton pump inhibitor use, or remote CDI history >6 months earlier). A total of 79 participants were randomly assigned to high-dose VE303 (8.0ร—10^9 CFUs; n=30), low-dose VE303 (1.6ร—10^9 CFUs; n=27), or placebo (n=22), taken orally once daily for 14 days. The primary efficacy end point was the proportion of participants with CDI recurrence at 8 weeks using a combined clinical and laboratory definition. Three prespecified analyses used successively broader definitions: (1) diarrhea consistent with CDI plus a toxin-positive stool sample; (2) diarrhea plus a toxin-positive, PCR-positive, or toxigenic culture-positive stool sample; and (3) diarrhea plus laboratory confirmation or, in the absence of a stool sample, treatment with a CDI-targeted antibiotic.
Introduction
Clostridioides difficile infection (CDI) is a major cause of healthcare-associated diarrhea, and recurrence after standard antibiotic treatment is common. The role of rationally defined nonpathogenic, nontoxigenic commensal Clostridia in preventing CDI recurrence is unknown. VE303 is a defined bacterial consortium of 8 strains of commensal Clostridia developed to restore colonization resistance. This phase 2 trial aimed to determine the efficacy of VE303 in adults at high risk for CDI recurrence and to identify the recommended dose for a phase 3 trial.

Why it matters

High-dose VE303 significantly reduced the risk of recurrent CDI compared with placebo in adults with laboratory-confirmed CDI and either prior episodes or high risk for recurrence. The lower recurrence rate with high-dose VE303 (13.8%) compared to low-dose (37.0%) and placebo (45.5%) suggests a dose-response effect. The study was limited by its phase 2 design, small sample size, and short follow-up. The authors conclude that a larger phase 3 study is needed to confirm these findings. The trial was registered with ClinicalTrials.gov (NCT03788434).

Who should read this

Pembaca Research Digest dan praktisi rumpun ini.

Opening member contentโ€ฆ